Olga Gryniewicz-Kwiatkowska

Dr. Olga Gryniewicz-Kwiatkowska

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Blood
Verified
Journal Article
Open access
PDF file
PKPaul G. Kemps
Paul G. Kemps
JPJennifer Picarsic
Jennifer Picarsic
BDBenjamin H Durham
Benjamin H Durham
ZHZofia Hélias-Rodzewicz
Zofia Hélias-Rodzewicz
LHLaura Sophia Hiemcke-Jiwa
Laura Sophia Hiemcke-Jiwa
JEJean-François Emile
Jean-François Emile
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.

1 February 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JSJan Styczyński
Jan Styczyński
KCKrzysztof Czyzewski
Krzysztof Czyzewski
MWM Wysocki
M Wysocki
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
AKA Kolodziejczyk-Gietka
A Kolodziejczyk-Gietka
PHPolish Society Of Paediatric Oncology And Haematology
Polish Society Of Paediatric Oncology And Haematology

11 October 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JWJadwiga Weclawek-Tompol
Jadwiga Weclawek-Tompol
ZZZuzanna Zakrzewska
Zuzanna Zakrzewska
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
FPFilip Pierlejewski
Filip Pierlejewski
EBEwa Bien
Ewa Bien
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, children present milder symptoms, with most having an asymptomatic course. We hypothesized that COVID-19 infection has a negative impact on the continuation of chemotherapy and increases nonrelapse mortality. Material and methods: This study was performed to assess the course of SARS-CoV-2 among children with hematological or oncological malignancies and its impact on cancer therapy. Records of SARS-CoV-2 infection in 155 children with malignancies from 14 Polish centers for pediatric hematology and oncology were collected and analyzed. Results: SARS-CoV-2 replication was observed in 155 patients. Forty-nine patients were symptomatic, with the following being the most common manifestations: fever (31 patients), gastrointestinal symptoms (10), coryza (13), cough (13) and headache (8). In children who were retested, the median time of a positive PCR result was 16 days (range 1–70 days), but 12.7% of patients were positive beyond day + 20. The length of viral PCR positivity correlated with the absolute neutrophil count at diagnosis. Seventy-six patients did not undergo further SARS-CoV-2 testing and were considered convalescents after completion of isolation. Antibiotic therapy was administered in 15 children, remdesivir in 6, convalescent plasma in 4, oxygen therapy in 3 (1—mechanical ventilation), steroids in 2, intravenous immunoglobulins in 2, and heparin in 4. Eighty patients were treated with chemotherapy within 30 days after SARS-CoV-2 infection diagnosis or were diagnosed with SARS-CoV-2 infection during 30 days of chemotherapy administration. Respiratory symptoms associated with COVID-19 and associated with oxygen therapy were present in 4 patients in the study population, and four deaths were recorded (2 due to COVID-19 and 2 due to progressive malignancy). The probability of 100-day overall survival was 97.3% (95% CI 92.9–99%). Delay in the next chemotherapy cycle occurred in 91 of 156 cases, with a median of 14 days (range 2–105 days). Conclusions: For the majority of pediatric cancer patients, SARS-CoV-2 infection does not result in a severe, life-threatening course. Our data show that interruptions in therapy are common and can result in suboptimal therapy.

5 July 2018 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMałgorzata Salamonowicz-Bodzioch
Małgorzata Salamonowicz-Bodzioch
TOTomasz Ociepa
Tomasz Ociepa
JFJ. Frączkiewicz
J. Frączkiewicz
ASA. Szmydki-Baran
A. Szmydki-Baran
MMM. Matysiak
M. Matysiak
JSJ. Styczyński
J. Styczyński
Clostridium difficile infection (CDI) is one of the most common causes of nosocomial infectious diarrhea in children during anticancer therapy or undergoing hematopoietic stem cell transplantation (HSCT) in Europe. Immunosuppression in these patients is a risk factor for CDI. Malignant diseases, age, acute graft-versus-host disease (aGVHD), HLA mismatch, or use of total body irradiation may play an important role in CDI course. The aim of this study was to evaluate the incidence, course, and outcome of CDI in children treated for malignancy or undergoing HSCT. Between 2012 and 2015, a total number of 1846 patients were treated for malignancy in Polish pediatric oncological centers (PHO group) and 342 underwent transplantation (HSCT group). In PHO group, episodes of CDI occurred in 210 patients (14%). The incidence of CDI was higher in patients with hematological malignancies in comparison to that with solid tumors. Patients with acute myeloblastic leukemia had shorter time to episode of CDI than those with acute lymphoblastic leukemia. Patients over 5 years and treated for acute leukemia had more severe clinical course of disease in PHO group. In HSCT group, CDI occurred in 29 (8%) patients. The incidence of CDI was higher in patients transplanted for acute leukemia. The recurrence rate was 14.7% in PHO and 20.7% in HSCT patients. CDI incidence was highest in patients with hematological malignancies. Most of patients experienced mild CDI. Age < 5 years and diagnosis other than acute leukemia were the positive prognostic factors influencing clinical CDI course.

1 May 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
KCKrzysztof Czyzewski
Krzysztof Czyzewski
PGPrzemyslaw Galazka
Przemyslaw Galazka
PZPatrycja Zalas-Wiecek
Patrycja Zalas-Wiecek
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
AGAgnieszka Gietka
Agnieszka Gietka
JSJan Styczynski
Jan Styczynski
Objectives: The analysis of epidemiology, risk factors and outcome of infections in children with malignant bone tumors (MBT) undergoing chemotherapy. Methods: In this retrospective nationwide multicenter cross-sectional study, a total number of 126 children with MBT including 70 with Ewing sarcoma (ES) and 56 with osteosarcoma (OSA) were screened for infections over a period of 72 consecutive months. Results: The risk of infection was 7.15-fold higher in patients with ES as compared to the OSA group, especially concerning bacterial infections (4.1-fold increase risk). Bacterial infections occurred in 74.3% patients with ES and in 41.1% with OSA. The median time from diagnosis to first infection was 4.9 months. 33.0% of bacterial episodes were diagnosed as bloodstream (BSI), 31.1% as gastrointestinal tract, 30.1% as urinary tract infection. Infection-related mortality (IRM) from bacterial infection was 6% and 15% in ES and OSA patients, respectively. Cumulative incidence was 7.1% for invasive fungal disease and 6.3% for viral infections. The only significant risk factor for IRM was time to infection ≥5 months since the beginning of chemotherapy. All patients who have died from infection had BSI and were in neutropenia. Conclusions: Infections in the children with MBT in our study occurred with high frequency, especially in patients with ES. The most frequent were bacterial infections, while fungal and viral infections were episodic. Among the bacterial infections, bloodstream, urinary tract and gastrointestinal tract infections occurred with similar frequency. All deceased patients died due to BSI. Bacterial infection occurring ≥5 months since the beginning of chemotherapy was a risk factor for death.

8 July 2013 in Mycoses
Verified
Journal Article
Closed access
PDF file
KDKatarzyna Dzierzanowska-Fangrat
Katarzyna Dzierzanowska-Fangrat
EREwa Romanowska
Ewa Romanowska
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
MMMarek Migdał
Marek Migdał
KWKatarzyna Witulska
Katarzyna Witulska
DDDanuta Dzierzanowska
Danuta Dzierzanowska